Agranulocytosis during treatment with chlozapine

Within six months of the introduction of the new antipsychotic drug clozapine in Finalnd, 17 cases of neutropenia or agranulocytosis were recorded amongst about 3000 patients treated. Agranulocytosis was fatal in eight patients, and in addition, two patients developed thrombocytopenia, and one patie...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical pharmacology 1977-03, Vol.11 (3), p.193
Main Authors: Idänpään-Heikkilä, J, Alhava, E, Olkinuora, M, Palva, I P
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Agranulocytosis - chemically induced
Agranulocytosis - epidemiology
Agranulocytosis - mortality
Clozapine - adverse effects
Clozapine - analysis
Clozapine - therapeutic use
Dibenzazepines - adverse effects
Drug Contamination
Drug Therapy, Combination
Female
Finland
Hematologic Diseases - chemically induced
Humans
Male
Middle Aged
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 3
container_start_page 193
container_title European journal of clinical pharmacology
container_volume 11
creator Idänpään-Heikkilä, J
Alhava, E
Olkinuora, M
Palva, I P
description Within six months of the introduction of the new antipsychotic drug clozapine in Finalnd, 17 cases of neutropenia or agranulocytosis were recorded amongst about 3000 patients treated. Agranulocytosis was fatal in eight patients, and in addition, two patients developed thrombocytopenia, and one patient leukaemia. As additional cases might well have been overlooked as banal infections, the risk of developing agranulocytosis during clozapine treatment was at least 0.5%. Impaired elimination of the drug or increased susceptibility of granulocyte precursors to clozapine, possibly due to some inherited characteristic, might explain the high incidence of complications.
format article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_856603</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>856603</sourcerecordid><originalsourceid>FETCH-LOGICAL-p523-3634357a795c32a5e4348ced1fcf12fd29d51a6d1211b9a526f63c2ac8c9d6863</originalsourceid><addsrcrecordid>eNotzrtuwjAUgGEPpeXSvkGHvEAk2yc-iUeEKEVCYmFHB1_AVW6yHVX06Rno9G-f_he24BxEibrmc7ZM6YdzoTSHN_baKEQOC8bX10j91A7mnocUUmGnGPprkaOj3Lk-F78h3wpza4c_GkPv3tnMU5vcx39X7PS1PW2-y8Nxt9-sD-WoJJSAUIGqqdbKgCTlKqga46zwxgvprdRWCUIrpBAXTUqiRzCSTGO0xQZhxT6f7DhdOmfPYwwdxfv5-Q0Pzcs9qw</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Agranulocytosis during treatment with chlozapine</title><source>Springer Online Journal Archives (Through 1996)</source><creator>Idänpään-Heikkilä, J ; Alhava, E ; Olkinuora, M ; Palva, I P</creator><creatorcontrib>Idänpään-Heikkilä, J ; Alhava, E ; Olkinuora, M ; Palva, I P</creatorcontrib><description>Within six months of the introduction of the new antipsychotic drug clozapine in Finalnd, 17 cases of neutropenia or agranulocytosis were recorded amongst about 3000 patients treated. Agranulocytosis was fatal in eight patients, and in addition, two patients developed thrombocytopenia, and one patient leukaemia. As additional cases might well have been overlooked as banal infections, the risk of developing agranulocytosis during clozapine treatment was at least 0.5%. Impaired elimination of the drug or increased susceptibility of granulocyte precursors to clozapine, possibly due to some inherited characteristic, might explain the high incidence of complications.</description><identifier>ISSN: 0031-6970</identifier><identifier>PMID: 856603</identifier><language>eng</language><publisher>Germany</publisher><subject>Adolescent ; Adult ; Aged ; Agranulocytosis - chemically induced ; Agranulocytosis - epidemiology ; Agranulocytosis - mortality ; Clozapine - adverse effects ; Clozapine - analysis ; Clozapine - therapeutic use ; Dibenzazepines - adverse effects ; Drug Contamination ; Drug Therapy, Combination ; Female ; Finland ; Hematologic Diseases - chemically induced ; Humans ; Male ; Middle Aged</subject><ispartof>European journal of clinical pharmacology, 1977-03, Vol.11 (3), p.193</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/856603$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Idänpään-Heikkilä, J</creatorcontrib><creatorcontrib>Alhava, E</creatorcontrib><creatorcontrib>Olkinuora, M</creatorcontrib><creatorcontrib>Palva, I P</creatorcontrib><title>Agranulocytosis during treatment with chlozapine</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><description>Within six months of the introduction of the new antipsychotic drug clozapine in Finalnd, 17 cases of neutropenia or agranulocytosis were recorded amongst about 3000 patients treated. Agranulocytosis was fatal in eight patients, and in addition, two patients developed thrombocytopenia, and one patient leukaemia. As additional cases might well have been overlooked as banal infections, the risk of developing agranulocytosis during clozapine treatment was at least 0.5%. Impaired elimination of the drug or increased susceptibility of granulocyte precursors to clozapine, possibly due to some inherited characteristic, might explain the high incidence of complications.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Agranulocytosis - chemically induced</subject><subject>Agranulocytosis - epidemiology</subject><subject>Agranulocytosis - mortality</subject><subject>Clozapine - adverse effects</subject><subject>Clozapine - analysis</subject><subject>Clozapine - therapeutic use</subject><subject>Dibenzazepines - adverse effects</subject><subject>Drug Contamination</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Finland</subject><subject>Hematologic Diseases - chemically induced</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><issn>0031-6970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1977</creationdate><recordtype>article</recordtype><recordid>eNotzrtuwjAUgGEPpeXSvkGHvEAk2yc-iUeEKEVCYmFHB1_AVW6yHVX06Rno9G-f_he24BxEibrmc7ZM6YdzoTSHN_baKEQOC8bX10j91A7mnocUUmGnGPprkaOj3Lk-F78h3wpza4c_GkPv3tnMU5vcx39X7PS1PW2-y8Nxt9-sD-WoJJSAUIGqqdbKgCTlKqga46zwxgvprdRWCUIrpBAXTUqiRzCSTGO0xQZhxT6f7DhdOmfPYwwdxfv5-Q0Pzcs9qw</recordid><startdate>19770311</startdate><enddate>19770311</enddate><creator>Idänpään-Heikkilä, J</creator><creator>Alhava, E</creator><creator>Olkinuora, M</creator><creator>Palva, I P</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>19770311</creationdate><title>Agranulocytosis during treatment with chlozapine</title><author>Idänpään-Heikkilä, J ; Alhava, E ; Olkinuora, M ; Palva, I P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p523-3634357a795c32a5e4348ced1fcf12fd29d51a6d1211b9a526f63c2ac8c9d6863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1977</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Agranulocytosis - chemically induced</topic><topic>Agranulocytosis - epidemiology</topic><topic>Agranulocytosis - mortality</topic><topic>Clozapine - adverse effects</topic><topic>Clozapine - analysis</topic><topic>Clozapine - therapeutic use</topic><topic>Dibenzazepines - adverse effects</topic><topic>Drug Contamination</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Finland</topic><topic>Hematologic Diseases - chemically induced</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Idänpään-Heikkilä, J</creatorcontrib><creatorcontrib>Alhava, E</creatorcontrib><creatorcontrib>Olkinuora, M</creatorcontrib><creatorcontrib>Palva, I P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Idänpään-Heikkilä, J</au><au>Alhava, E</au><au>Olkinuora, M</au><au>Palva, I P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Agranulocytosis during treatment with chlozapine</atitle><jtitle>European journal of clinical pharmacology</jtitle><addtitle>Eur J Clin Pharmacol</addtitle><date>1977-03-11</date><risdate>1977</risdate><volume>11</volume><issue>3</issue><spage>193</spage><pages>193-</pages><issn>0031-6970</issn><abstract>Within six months of the introduction of the new antipsychotic drug clozapine in Finalnd, 17 cases of neutropenia or agranulocytosis were recorded amongst about 3000 patients treated. Agranulocytosis was fatal in eight patients, and in addition, two patients developed thrombocytopenia, and one patient leukaemia. As additional cases might well have been overlooked as banal infections, the risk of developing agranulocytosis during clozapine treatment was at least 0.5%. Impaired elimination of the drug or increased susceptibility of granulocyte precursors to clozapine, possibly due to some inherited characteristic, might explain the high incidence of complications.</abstract><cop>Germany</cop><pmid>856603</pmid></addata></record>
fulltext fulltext
identifier ISSN: 0031-6970
ispartof European journal of clinical pharmacology, 1977-03, Vol.11 (3), p.193
issn 0031-6970
language eng
recordid cdi_pubmed_primary_856603
source Springer Online Journal Archives (Through 1996)
subjects Adolescent
Adult
Aged
Agranulocytosis - chemically induced
Agranulocytosis - epidemiology
Agranulocytosis - mortality
Clozapine - adverse effects
Clozapine - analysis
Clozapine - therapeutic use
Dibenzazepines - adverse effects
Drug Contamination
Drug Therapy, Combination
Female
Finland
Hematologic Diseases - chemically induced
Humans
Male
Middle Aged
title Agranulocytosis during treatment with chlozapine
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T13%3A35%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Agranulocytosis%20during%20treatment%20with%20chlozapine&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=Id%C3%A4np%C3%A4%C3%A4n-Heikkil%C3%A4,%20J&rft.date=1977-03-11&rft.volume=11&rft.issue=3&rft.spage=193&rft.pages=193-&rft.issn=0031-6970&rft_id=info:doi/&rft_dat=%3Cpubmed%3E856603%3C/pubmed%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p523-3634357a795c32a5e4348ced1fcf12fd29d51a6d1211b9a526f63c2ac8c9d6863%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/856603&rfr_iscdi=true